Former Beckman Coulter Dr. Eyal Kalo to join Innocan Pharma’s Expanding R&D Team

0
50

Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – March 4, 2022) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”) is pleased to announce the appointment of Dr. Eyal Kalo as Research and Development Project Manager. In this new role Dr. Eyal Kalo will coordinate internal and external R&D projects, assist in the development progress and manage the cross functional of Innocan’s pharma projects.

About Dr.Eyal Kalo

Dr.Eyal Kalo earned his PhD from the Weizmann Institute of Science mastering in the field of cancer research. Dr. Kalo completed his studies in 2010 and joined the biotechnology industry where he gained expertise in leading various R&D projects from concept to launch in the field of medical diagnostics, and natural medicine. Dr. Kalo worked as a scientific team leader at the molecular diagnostic division of Beckman Coulter and was responsible for the development of an FDA approved molecular-based diagnostic assay to detect HIV in patients. Prior to that, he served as a senior project manager at IBR Ltd., a company that is under IFF – International Flavors & Fragrances, Inc. structure and develops, manufactures and markets innovative and proprietary natural active ingredients.

Dr. Kalo stated: “Innocan Pharma aspires to bring to the market a variety of pharmaceutical solutions in the near-coming future, and I’m thrilled to be able to assist and contribute from my vast experience to Innocan.”

“We are pleased to welcome Dr. Eyal Kalo to the Innocan Research and Development team,” said CEO Iris Bincovich. “With his considerable science research expertise, Dr. Kalo is well-suited to be our R&D project manager as we pursue our goal to bring our platforms and technologies to the market. I am confident that Dr. Kalo will provide the leadership and strategic direction to enable us to advance our development of proprietary innovations.”

About Innocan

Innocan Pharma is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan Pharma and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administered by inhalation, will be tested against a variety of lung infections.

Innocan Pharma signed a worldwide exclusive license agreement with Yissum, the commercial arm of The Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administered by injection. Innocan Israel plans, together with Professor Barenholz, to test the liposome platform on several potential conditions. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan Israel each have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
[email protected]

Lytham Partners, LLC
Ben Shamsian CPA | Vice President
Direct: 646-829-9701; Cell: 516-652-9004
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the success of its research activities, collaborations, the size of the markets in Japan and Asia, further research of treatments towards other conditions, the treatment of other conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/115611

LEAVE A REPLY

Please enter your comment!
Please enter your name here